Core Insights - The company has received a new patent for its LIBERTY Endovascular Robotic System, bringing its total to 12 granted patents globally and 57 pending applications, which enhances its intellectual property portfolio [1][2] - The new patent allows for modular capabilities in the robotic system, potentially expanding its application to a wider range of endovascular procedures, thereby increasing the Total Addressable Market (TAM) [1][2] - The company aims to address over 6 million annual endovascular procedures in the U.S., significantly higher than the current estimate of 2.5 million procedures [2][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [4] - The company has developed the first single-use, fully disposable endovascular robotic system, which aims to remove traditional barriers to accessing advanced robotic systems [4]

Financial Performance - For the six months ended June 30, 2025, the net loss was $6,101,000, an increase of 26% from the net loss of $4,836,000 in the same period of 2024[13] - The company reported a basic and diluted net loss per share of $0.10 for the three months ended June 30, 2025, compared to $0.17 in 2024[13] - For the six months ended June 30, 2025, the company reported a net loss of $6,101,000, compared to a net loss of $4,836,000 for the same period in 2024, representing a 26.2% increase in losses[22] - The net loss for the three months ended June 30, 2025, was $3,500 million, compared to a net loss of $2,465 million in the same period of 2024, reflecting a 42% increase in losses[95] Assets and Liabilities - As of June 30, 2025, total assets increased to $33,131,000 from $6,031,000 as of December 31, 2024[11] - Total current assets increased to $32,891,000 as of June 30, 2025, up from $5,819,000 as of December 31, 2024[11] - The company’s total liabilities increased to $2,774,000 as of June 30, 2025, compared to $2,501,000 as of December 31, 2024[11] - The total current liabilities rose to $2,727,000 as of June 30, 2025, compared to $2,460,000 at the end of 2024, reflecting a 10.9% increase[11] Shareholder Equity - Total shareholders' equity increased to $30,357,000 as of June 30, 2025, compared to $3,530,000 at the end of 2024[11] - The company’s accumulated deficit as of June 30, 2025, was $97,045,000, up from $90,944,000 as of December 31, 2024[11] Cash Flow and Financing - Cash and cash equivalents rose to $4,082,000 compared to $3,114,000 at the end of 2024, marking an increase of 31%[11] - Net cash flows used in operating activities for the six months ended June 30, 2025, were $5,447,000, compared to $4,377,000 in 2024[22] - The company raised $32,558,000 from the issuance of common stock and warrants during the six months ended June 30, 2025[22] - The company raised approximately $13,275,000 in gross proceeds from the exercise of outstanding Series G and F preferred investment options during the period from July 1, 2025, to August 8, 2025[96] Research and Development - Research and development expenses for the three months ended June 30, 2025, were $2,111,000, up 49% from $1,417,000 in 2024[13] - The Company has not generated any revenues from its operations to date and expects to incur additional losses for the foreseeable future due to ongoing research and development activities[29] - The company expects to continue incurring additional losses due to ongoing research and development and pre-commercialization activities[29] Grants and Royalties - The Company has received approximately $1.88 million in grants from the Israeli Innovation Authority since 2013, with a repayment obligation of 3.0% - 5% of future sales linked to these grants[53] - The Company received a grant of approximately $83,000 from the Ministry of Economy for expenses related to the LIBERTY® Endovascular Robotic Surgical System, with a royalty obligation of 3% on future sales[56] - The company is obligated to pay royalties of 3.0% - 5% on future sales related to the IIA grants, linked to the exchange rate of the dollar to the New Israeli Shekel[54] Marketable Securities - Marketable securities increased significantly to $28,592,000 as of June 30, 2025, from $2,356,000 at the end of 2024[11] - The company had cash equivalents and marketable securities of approximately $32,674,000 as of June 30, 2025, excluding restricted cash[29] - The company’s marketable securities increased from $2.36 million as of December 31, 2024, to $28.59 million as of June 30, 2025[43] Operational Updates - The Company suspended its Self-Cleaning Shunt project in October 2022 and returned related intellectual property to the Technion Research and Development Foundation in 2023[58] - The Company is closely monitoring the impact of ongoing military operations in Israel on its clinical and regulatory activities, although no material adverse effects have been reported as of the issuance date[32] - The company has one operating and reportable segment focused on the development of robotic devices for endoluminal surgery[93] Stock and Shareholder Actions - The company increased its authorized shares to 120,000,000 during the annual meeting on June 10, 2025[76] - The company granted options to purchase an aggregate of 80,000 shares to the CEO and 52,500 shares to certain executives at an exercise price of $1.25, with vesting contingent on performance conditions[91] - The company issued 3,433,880 shares under the ATM Agreement in 2024, generating gross proceeds of approximately $3,756[78] Legal and Compliance - The Company recorded a net non-operating loss of $1,111 from a legal settlement in 2023, with a current liability of $2,211 and a current asset of $1,335 as of December 31, 2023[68] - The company received a judgment of approximately $316 from litigation against Alliance Investment Management, recorded as other income[69] - The company has adopted ASU 2023-07 for segment reporting, effective for the fiscal year ended December 31, 2024, enhancing disclosures about significant segment expenses[50]

Core Insights - Microbot Medical Inc. has received a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority to enhance its manufacturing capabilities for the LIBERTY® Endovascular Robotic System, pending FDA marketing clearance [1][2][3] Group 1: Company Developments - The grant is expected to strengthen the company's balance sheet and operational readiness as it awaits FDA's decision on marketing clearance [3] - The Israel Innovation Authority recognized the company's recent achievements, the target market's size, the competitive advantages of a single-use robot, and the expected benefits to healthcare systems [2] - The LIBERTY® System is an investigational device currently pending FDA 510(k) clearance and is not available for sale in the U.S. [3][4] Group 2: Market Positioning - Microbot Medical aims to redefine endovascular robotics and improve care quality for patients globally with its single-use, fully disposable robotic system [4] - The company believes the grant validates its technology and reflects the IIA's confidence in its ability to scale manufacturing and meet business objectives [2][3]

Core Insights - Microbot Medical Inc. has appointed Christina Bailey as the new Vice President of Sales, bringing 20 years of medical device sales experience and a successful track record in leading commercial teams [1][2][3] - The company is preparing for the anticipated launch of its LIBERTY Endovascular Robotic System, which is currently pending FDA 510(k) clearance and not available for sale in the U.S. [3][4] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to enhance patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system aimed at overcoming traditional barriers to advanced robotic systems [4] Leadership and Experience - Christina Bailey has held various sales leadership roles at notable companies such as Boston Scientific, Abbott, Stryker, and Intuitive Surgical, equipping her with insights to drive growth and innovation [2] - Her previous role as Vice President of US Sales at Endologix involved building and scaling sales teams and achieving significant sales milestones [2]

Core Insights - Microbot Medical Inc. is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, highlighting the growth and innovation in the endovascular robotics field driven by market demand [1][3] - The session will feature discussions on emerging technologies in the peripheral vascular, neurovascular, and cardiovascular spaces, with a focus on educating the medical community about the LIBERTY Endovascular Robotic System [2][3] - The SRS aims to foster education and collaboration in robotic surgery, providing opportunities for multi-centric studies and training for young professionals in the field [4] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [6] - The company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to remove barriers to accessing advanced robotic systems [6] - The LIBERTY system is currently pending FDA 510(k) clearance and is not available for sale in the U.S. as the company strengthens its sales and marketing infrastructure for its launch [5]

Core Insights - Microbot Medical Inc. has been added to the Russell Microcap Index, effective June 30, 2025, enhancing its visibility in the market [1][2] - The inclusion reflects the company's strong execution and momentum, particularly in relation to its LIBERTY Endovascular Robotic System and ongoing FDA interactions [2] - The Russell US Indexes reconstitution captures the 4,000 largest US stocks, and membership in the Russell Microcap Index ensures automatic inclusion in relevant growth and value style indexes [2][3] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [4] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3]

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]

Core Viewpoint - Microbot Medical Inc. (MBOT) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Microbot Medical signifies an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for fair value calculations [5]. - For Microbot Medical, the recent increase in earnings estimates suggests an improvement in the company's underlying business, which should positively influence stock performance [6]. Performance of Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Microbot Medical to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Recent Earnings Estimate Trends - For the fiscal year ending December 2025, Microbot Medical is expected to earn -$0.32 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 38.5% over the past three months [9].

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]

Group 1 - Microbot Medical Inc. has been selected for inclusion in the preliminary list of additions to the Russell Microcap Index, effective after U.S. market close on June 27, 2025 [1] - Membership in the Russell Microcap Index is determined by market capitalization rankings and style attributes, and it remains in place for one year [2] - Russell indexes are utilized by investment managers and institutional investors for index funds and serve as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] Group 2 - Microbot Medical is a pre-commercial stage medical technology company focused on improving patient care globally [4] - The company has developed the LIBERTY Endovascular Robotic System, which is the world's first single-use, fully disposable endovascular robotic system [4]